A variety of other surface targets are currently under evaluation in prostate cancer, including bombesin [13], prostate stem cell antigen (PSCA) [14], CUB-domain-containing protein 1 (CDCP-1), CD46 [15,16], human kallikrein 2 (hK2) [17], delta-like ligand 3 (DLL3) [18,19,20], and TROP-2 [21]. The gene discussed is CDCP1; the disease is prostate cancer.